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Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. With-
out  an effective therapy, patients may progress quickly to functional disability. Recently,
depletion of B cells emerged as a new approach for the treatment of autoimmune diseases,
including JIA.
We  describe six cases of JIA patients followed at a referral center for Rheumatology and
Pediatric Rheumatology, submitted to treatment with rituximab (RTX) after refractoriness
to  three anti-TNF agents.
Patients received RTX cycles with two infusions every six months. Response to treatment
was assessed by DAS28, HAQ/CHAQ, and an overall assessment by the doctor and the patient.
Of  our six patients, four were girls (mean age at onset of disease: 6.1 years; mean disease
evolution time: 15.1 years; mean age upon receiving RTX: 21.6 years). Four patients belonged
to  polyarticular subtype (1 rheumatoid factor [RF]-negative, 3 FR-positive), a patient with
systemic JIA subtype with a polyarticular course and arthritis related to enthesitis. Of our
six  patients, ﬁve responded to treatment; and during the course of 12 months, the clinical
response was maintained, although not sustained. However, discontinuation by infusion
reactions caused the withdrawal of RTX in two patients.
The use of RTX in JIA is restricted to cases refractory to other biological agents and, even
considering that this study was held in a small number of advanced patients, RTX provedto  be an effective therapeutic option.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Uso  de  rituximabe  em  adultos  jovens  com  diagnóstico  de  artrite
idiopática  juvenil  refratária  ao  tratamento  convencional:  relato  de  6  casos
Palavras-chave:
Artrite idiopática juvenil
Crianc¸as
Rituximabe
Refratariedade
r  e  s  u  m  o
A artrite idiopática juvenil (AIJ) é a doenc¸a reumática mais frequente na infância. Sem
terapia efetiva, os pacientes podem evoluir rapidamente para incapacidade funcional.
Recentemente, a deplec¸ão dos linfócitos B surgiu como nova abordagem para o tratamento
de  doenc¸as autoimunes, incluindo a AIJ.
Descrevemos seis casos de pacientes com AIJ, acompanhados em um centro de referência
em  Reumatologia e Reumatologia Pediátrica, submetidos ao tratamento com rituximabe
(RTX) após refratariedade a três anti-TNF.
Os pacientes receberam ciclos de RTX com duas infusões a cada seis meses. A resposta ao
tratamento foi avaliada pelo DAS28, HAQ/CHAQ, avaliac¸ão global do médico e do paciente.
Dos  seis pacientes, quatro eram meninas (média de idade de início da doenc¸a: 6,1 anos;
média de tempo de evoluc¸ão de doenc¸a: 15,1 anos; média de idade ao receber RTX: 21,6 anos).
Quatro pacientes pertenciam ao subtipo poliarticular (1 fator reumatoide (FR) negativo, 3 FR
positivo), um paciente com AIJ subtipo sistêmico com evoluc¸ão poliarticular e um com artrite
relacionada à entesite. Dos seis pacientes, cinco responderam ao tratamento e durante a
evoluc¸ão de 12 meses, a resposta clínica foi mantida, embora não sustentada. No entanto, a
descontinuac¸ão  por reac¸ões infusionais motivaram a suspensão do RTX em dois pacientes.
O  uso do RTX em AIJ é restrito aos casos refratários a outros biológicos e, mesmo tendo
sido realizada em um número pequeno de pacientes e de forma tardia, mostrou ser uma
opc¸ão  terapêutica eﬁcaz.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
I
J
r
m
a
c
B
p
r
a
J
a
M
S
n
r
o
A
(
H
v
m
A
was 21.6 years (18–26 years) (Table 1). Uveitis was not observed
in any patient.
Table 1 – Clinical data of 6 patients treated with
rituximab.
Age at
diagnosis
Age at
rituximab
JIA subtype
DAB 5 19 Polyarticular RF +
DC 5 24 Systemic
DSS 7 21 Enthesitis-related
arthritisntroduction
uvenile idiopathic arthritis (JIA) is the most common chronic
heumatic disease in childhood and without appropriate treat-
ent it can quickly result in functional disability.1
Recently, B lymphocyte depletion emerged as a new ther-
peutic approach for JIA and SLE.2–7 Rituximab (RTX) is a
himeric monoclonal antibody directed against the CD20 pre-
 cells and mature B cells with efﬁcacy and safety in adult
atients with rheumatoid arthritis (RA) with an inadequate
esponse to disease-modifying drugs (DMARDs) and anti-TNF-
lpha inhibitors.8–12
The objective of this study was to describe six patients with
IA followed in a Pediatric Rheumatology Unit between 1993
nd 2014 who  underwent treatment with RTX.
ethods
ix patients diagnosed with JIA according to the ILAR (Inter-
ational League of Associations of Rheumatology) criteria13
eceived RTX cycles with two intravenous infusions of 1 g each
n days 1 and 15, every six months.
The clinical response was measured by DAS28 (Disease
ctivity Score in 28 joints),14 erythrocyte sedimentation rate
ESR), Health Assessment Questionnaire (HAQ)15 or the Child
ealth Assessment Questionnaire (CHAQ)16 and evaluation of
isual analog scale (VAS) of the patient and the physician.
The assessments were performed before and every six
onths of treatment. According to EULAR (European League
gainst Rheumatism) criteria, the patients were classiﬁed asgood responders if improvement in DAS28 was greater than
1.2, moderate responders if between 0.6 and 1.2, and non-
responders if less than 0.6, in two consecutive measurements.
Clinical remission was deﬁned as a DAS28 less than 2.6.17
Primary failure was deﬁned as a reduction lower than
0.6 of DAS28 after 12 weeks and secondary failure, such as
loss of efﬁcacy over 24 weeks in patients who had responded
in the ﬁrst 12 weeks.17 Adverse events were recorded.
Case  report
The mean onset age of the disease was 6.1 years and mean
disease duration was 15.1 years. The mean age at start of RTXFAGS 7 26 Polyarticular RF−
MILP 4 20 Polyarticular RF+
ELS 9 18 Polyarticular RF+
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Case  1
DAB, 19 years old, female, erosive polyarticular JIA diagnosed
since the age of ﬁve, positive rheumatoid factor (RF), being
followed since the age of 11.
The patient has taken glucocorticoids (GCs), methotrexate
(up to 1 mg/kg/week) for ﬁve years, cyclosporine (5 mg/kg/day)
for ﬁve months and cyclophosphamide (up to 1 g/m2) for
three months with partial response to all treatments.
She initiated treatment with inﬂiximab (5 mg/kg every six
weeks) for two years, followed by etanercept (0.8 mg/kg/week)
for four months and adalimumab (24 mg/m2) for four
years.
Due to refractoriness and intense disease activity, RTX was
introduced at 19 years of age, combined with leﬂunomide
(20 mg/day) and prednisone at an initial dose of 20 mg,  with
progressive tapering up to withdrawal.
After 6 months of the ﬁrst intravenous infusion, the patient
presented clinical improvement. Currently, the patient is clin-
ically stable, with no arthritis and no morning stiffness. She
remains on leﬂunomide, and is currently receiving the fourth
cycle of RTX.
Case  2
DC, 25 years, male, systemic onset JIA and polyarticular
course, negative RF, diagnosed since the age of ﬁve, started
follow-up at this clinic two years later.
Initially, the patient was on indomethacin (2 mg/kg/day)
and methotrexate (1 mg/kg/week) associated with GCs (up
to 1 mg/kg/day). When he was 14, he presented macrophage
activation syndrome, with pulse therapy being performed
with intravenous methylprednisolone, and cyclosporine
being started (5 mg/kg/day). After two years thalidomide
(2.5 mg/kg/day) was initiated, with partial response. When he
was 19, he started inﬂiximab (5 mg/kg every 6 weeks), develop-
ing anaphylaxis in the 9th dose. He switched to adalimumab
(24 mg/m2) and etanercept (0.8 mg/kg/week), with secondary
failure after 9 and 10 months, respectively.
RTX was started at 24 years old, presenting sustained
response, although with infusion reactions controlled with the
use of intravenous GC, antihistamines and a decrease in infu-
sion rate. He was concomitantly on cyclosporine (150 mg/day)
and prednisone (20 mg/day). However, after the fourth cycle of
RTX, the patient developed serum sickness, and discontinued
the treatment.
After stopping RTX, the disease became more  active,
requiring other medications and he had primary failure to
tocilizumab (8 mg/kg/dose) and abatacept (10 mg/kg/dose) and
was referred to autologous bone marrow transplantation
(ABMT).
Case  3
DSS, 26, male, diagnosed with enthesitis-related arthritis
(ERA) JIA since the age of seven. He began follow-up when
he was 13 years old. The evolution was polyarticular erosive,
associated with severe intestinal involvement, with Crohn’s
disease being diagnosed. 0 1 5;5 5(6):536–541
He took methotrexate (up to 1 mg/kg/week) for 10 years,
sulfasalazine (40 mg/kg/day) for ﬁve years, plus methylpred-
nisolone and cyclophosphamide intravenous pulse therapy
(up to 1 g/m2) for one year, and multiple joint injections with
GCs. He started inﬂiximab (5 mg/kg/dose every 6 weeks) with
good initial response and failure after two years of treatment.
He used cyclosporine (5 mg/kg/day) and methylprednisolone
pulse therapy, with no response for one year. Adalimumab
(24 mg/m2) was introduced but there was no response after
four months of treatment (primary failure).
When he was 21, he received the 1st cycle of RTX. He
showed signiﬁcant joint improvement after 12 months. How-
ever, it had to be discontinued due to recurrence of ﬁstulizing
intestinal disease. Although he previously had secondary fail-
ure to IFX, this was reintroduced combined with methotrexate
(25 mg/week) and prednisone (20 mg/day). However, due to dis-
ease activity and refractoriness, ABMT was indicated.
Case  4
FAGS, 32, female, erosive polyarticular JIA diagnosed since
seven years of age, negative RF, followed since she was 15 years
old.
She presented polyarthritis of small and large joints,
with good response to treatment with methotrexate (up to
1 mg/kg/week) and tapered doses of GCs in the ﬁrst year. She
remained asymptomatic until she was 20 years old, when
arthritis reappeared.
In the ﬁrst year of recurrence, the patient was restarted
on methotrexate (25 mg/week) and prednisone (20 mg/day).
Due to elevated transaminase levels, the dose of methotrexate
was reduced (15 mg/week) and sulfasalazine (40 mg/kg/day)
and chloroquine (5 mg/kg/day) were associated. At 24 years
old, leﬂunomide (20 mg/day) was started, but there was no
response after twelve months. She presented primary fail-
ure to the three anti-TNF blockers, and RTX was started at
the age of 26. Concomitant to treatment, the patient received
methotrexate (25 mg/week) and prednisone (10 mg/day). Six
months after the ﬁrst intravenous infusion there was a sig-
niﬁcant improvement in pain while synovitis persisted. She
maintained disease activity although with satisfactory results,
according to the EULAR response. After 12 months of treat-
ment with RTX, cyclosporine (150 mg/day) was introduced
with no success.
After the fourth cycle of RTX, the patient presented clin-
ical worsening (secondary failure) and it was replaced by
tocilizumab (8 mg/kg/dose) with partial response. At present,
she is on abatacept (10 mg/kg/dose), but with poor response
and the need for multiple intra-articular injections and high
doses of prednisone (20 mg/day). Given the refractoriness of
the case, the patient was referred to ABMT.
Case  5
MILP, 20, female, polyarticular JIA since the age of four, positive
RF, followed since 12 years old.
She had already received methotrexate, had gastroin-
testinal intolerance, and it was replaced by azathio-
prine (2 mg/kg/day). Subcutaneous methotrexate (up to
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Table 2 – Clinical and laboratory progress of patients after treatment with rituximab.
Patient DAB DC DSS FAGS MILP ELS
DAS28
Initial 4.77 5.02 7.21 8.42 5.19 4.28
6 months 3.25 4.32 5.12 6.61 4.31 4.09
12 months 1.66 3.08 4.05 4.28 3.21 2.58
18 months 1.38 3.12 4.78 4.32 4.36
24 months 3.67 4.95 7.41
HAQ/CHAQ
Initial 0.875 1.5 2.25 1.75 2.25 0.5
6 months 0 1.25 2.0 1.25 2.0 0.25
12 months 0 0.5 1.75 0.75 2.11 0
18 months 0 0.5 2.0 1.125 2.25
24 months 0.5 2.0 1.5
PtGA
Initial 8 9 10 8 6 6
6 months 1 5 9 6 6 4
12 months 1 5 7 4 5 0
18 months 1 4 5 4 7
24 months 4 7 5
PhGA
Initial 6 8 10 10 6 4
6 months 1 5 9 9 7 3
12 months 1 5 9 9 5 1
18 months 1 5 9 9 7
24 months 5 10 10
ESR (mm/1st.h)
Initial 26 32 19 23 78 62
6 months 8 28 25 42 64 54
12 months 28 20 15 30 15 40
18 months 7 26 28 17 23
24 months 25 45 125
CRP (mg/dL)
Initial 14 10.2 41 52 1.54 7.1
6 months 3.7 7.1 35.1 26.3 2.36 18.2
12 months 17 5.8 15.8 11.7 0.84 13.6
18 months <6 4.2 22.5 15.9 1.87
24 months 4.9 26.4 64.8
Adverse events/complications
6 months – – – – Pre-medication
Infusion reaction
–
12 months – Infusion reaction Infusion reaction Infusion reaction Infusion reaction Infusion reaction
18 months – Infusion reaction Infusion reaction Infusion reaction Infusion reaction Infusion reaction
24 months Infusion reaction Infusion reaction Infusion reaction Infusion reaction Infusion reaction
Response to treatment Yes Yes Yes Yes Yes Yes
DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment Questionnaire; CHAQ, Child Health Assessment Questionnaire; PtGA,
patient’s global assessment of visual-analogical scale; PhGA, physician’s global assessment of visual-analog scale; CRP, C reactive protein; ESR,
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 mg/kg/week) and intravenous pulse therapy with methyl-
rednisolone were started.
At the age of 12, inﬂiximab (5 mg/kg every 6 weeks) was
tarted in combination with cyclosporine (5 mg/kg/day), with
artial response after one year. After two years, a com-
ination of methotrexate and leﬂunomide was introduced
20 mg/day) with good response for nine months. At the age
f 15 etanercept (0.8 mg/kg/dose) was started and bilateral hip
rthroplasty was performed, and as she presented clinicaland laboratory disease activity, adalimumab (24 mg/m2) was
started at 16 years of age, with good response for one year.
At the age of 20, she had severe clinical and laboratory
inﬂammatory activity and received the 1st cycle of RTX. She
remained on methotrexate (1 mg/kg/week) and GCs (up to
0.5 mg/kg/day). She received a second intravenous infusion
of RTX and due to infusion reaction, the infusion rate had to
be slowed. During disease progress, the patient always main-
tained clinical and laboratory activity, requiring increased
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doses of GCs. Due to refractoriness of the disease, treatment
with tocilizumab was indicated.
Case  6
ELS, 20, female, erosive polyarticular JIA positive RF, since she
was 9 years old and on treatment since 10 years of age.
She had already received GCs (up to 1 mg/kg/day) orally for
ﬁve months with signiﬁcant adverse events. At the ﬁrst visit,
methotrexate (0.4 mg/kg/week) and naproxen were initiated,
and GCs tapered. During follow-up, intravenous pulse therapy
with methylprednisolone was carried out due to inﬂamma-
tion, anemia and persistence of the joint disease.
When she was 10, cyclosporin (up to 5 mg/kg/day) was
associated, and disease activity was maintained. After
a year, therapy with inﬂiximab was initiated (5 mg/kg every 6
weeks). At 13 years old, therapy with adalimumab (24 mg/m2)
was initiated, with good response for the ﬁrst two years.
After this period, a treatment was conducted with etanercept
(0.8 mg/kg/dose) for 11 months with poor response, and RTX
was indicated.
She received the 1st cycle of RTX when she was 18, with
clinical improvement for three months. After three months
of medication, there was clinical and laboratory worsening
and infection. However, in the following months, the patient
had signiﬁcant improvement in pain. The patient is awaiting
a fourth dose of RTX in combined use with subcutaneous MTX
(40 mg/week).
Discussion
RTX is an alternative therapy for refractory JIA patients.2,3,5–7
There are no controlled clinical trials with RTX in JIA and evi-
dence is limited to case series reports.6,7,18,19 The dose and
dosing intervals were determined taking into account the
experience and clinic logistics.
The clinical improvement observed by patients treated
with RTX suggests an important role for B cells in JIA
(Table 2).2,6,19,20 It was observed that in the children joints with
JIA there is oligoclonal expansion of B cells and increased IL-
12 production, and subsequent activation of T cells. In adults,
there is B cell depletion in blood and synovial tissue.10
All six patients responded to treatment at six and
12 months, but the clinical response was not maintained in
three of them, experiencing disease activity and refractori-
ness, since half of the patients had indication of ABMT. It is
also important to note that RTX was introduced late and after
failure to three anti-TNF blockers. Thus, B lymphocyte deple-
tion therapy, even though it was employed in a small number
of patients and belatedly, proved to be an effective and safe
therapeutic option in half the cases.
Randomized controlled and pivotal trials of RTX showed
that efﬁcacy was greater in adult patients with positive
RF or anti-citrullinated protein antibodies, highlighting the
21–23humoral response in these patients. In our study, half of
the sample did not have RF and none of the patients had anti-
citrullinated protein antibodies. This aspect did not affect the
therapeutic response in the short and medium term, although,
1 0 1 5;5 5(6):536–541
interestingly, it was these patients who did not claim beneﬁts
and have been referred to the ABMT.
Adverse events observed in our patients were similar to
those described in the literature. The main one was the
infusion reaction that occurred in two patients and led to per-
manent discontinuation of the medication despite adequate
response of the disease.
Some limitations may be listed, such as the small num-
ber of patients, lack of data on the CD19 cell count and
radiographic information of structural damage in the initial
evaluation and follow-up. However, the data are consistent
with the population of real life in this age group.
Thus, RTX is a treatment option in active, severe JIA and
unresponsive to DMARDs and anti-TNF blockers. The safety
and efﬁcacy demonstrated by this study should encourage
studies with more  patients, in order to determine the possi-
bility of a window of opportunity in patients with JIA.
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